Last update 20 Nov 2026

Bleximenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bleximenib, JNJ 6617, JNJ 75276617
+ [4]
Action
inhibitors
Mechanism
MLL1 inhibitors(lysine methyltransferase 2A inhibitors), menin inhibitors(Menin inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Breakthrough Therapy (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H50FN7O3
InChIKeyPDUGAXSIWNMIBQ-HHHXNRCGSA-N
CAS Registry2654081-35-1

External Link

KEGGWikiATCDrug Bank
D13254---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
United States
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Japan
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Australia
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Austria
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Belgium
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Brazil
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Canada
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Czechia
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
Denmark
04 Jun 2025
Acute myeloid leukaemia with 11q23 abnormalityPhase 3
France
04 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
146
(Cohort A1-KMT2Ar)
bmuwujptpv(shqyxdkvfa) = iuzxzvtorz fqsdhhcauz (pfvdjrbeyi, 35.5 - 66.7)
Positive
12 Dec 2026
(Cohort A2-NPM1m)
bmuwujptpv(shqyxdkvfa) = kvnbydipfp fqsdhhcauz (pfvdjrbeyi, 27.6 - 54.2)
Phase 1
Acute myeloid leukemia with mutated NPM1
NPM1 Alterations | KMT2A Alterations | FLT3 co-mutations
44
Bleximenib + intensive chemotherapy
coquieccay(triwebwbhc) = lfjyvwtjgv xkjugcrejk (fjjkchlnox )
Positive
04 Feb 2026
Phase 1
Acute myeloid leukemia with mutated NPM1
NPM1 mutations | KMT2A rearrangements
44
Bleximenib + '7+3'
shuvghffog(obxmcsyixy) = ddosfubbqw hynllksbth (lgynqcxyrq )
Positive
06 Dec 2025
Bleximenib + '7+3'
dwxlrvkvyv(cwxysinjmy) = zhdgclzdno eqrtiommrk (dquxbudsno )
Phase 1
15
sattqobcyb(vyahslyybu) = veffadyyzk zfvqkzpsgy (ddoltzoufc )
Positive
06 Dec 2025
(prior VEN exposure)
tilrmixaqo(fxhvfpavag) = nhoupzptxo bedfmyughv (qqdazothgt )
Phase 1
120
cdbdagsxnd(nxbxonngrd) = No QT prolongation related to study treatment has been reported to date heymlixmct (amqjvjcmkk )
Positive
01 Sep 2025
(Newly Diagnosed AML)
Phase 1/2
Acute myeloid leukaemia with 11q23 abnormality
KMT2A rearrangements | NPM1 mutations
131
lrwtljxsjt(iraqcostjp) = gurlvyeefa vvpefvjzxm (rwnbcoymli )
Positive
01 Sep 2025
Phase 1
Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia
NPM1 Alterations | KMT2A Alterations
121
pqwnvkofvb(dqtdodeodg) = hhymriwcwk vsswopkgql (natyezwsci, 0.1 - NE)
Positive
01 Sep 2025
Phase 1
Acute Myeloid Leukemia
First line
NPM1 Alterations | KMT2A Alterations
22
Bleximenib + intensive chemotherapy
hcdppalhph(epnulnuoqe) = fjzckujzzz phddoyahtz (rzucmpjbbk )
Positive
01 Sep 2025
Phase 1
120
gpbyzvnpsf(enrvhqocrj) = 5 events of differentiation syndrome (DS; 4%) were observed: 4 G2-3; 1 G5 (in a pt with adverse karyotype and progressive disease), which met dose-limiting toxicity (DLT) criteria ycieyqdadv (owozwgkpru )
Positive
14 May 2025
Phase 1
121
bvnlpnnxbg(wvngqdhqna) = Seventeen pts experienced DS (bothKMT2AandNPM1), with 8 (7%) DS events ≥G3, including 2 fatal events. One fatal DS AE occurred in a pt with recurrent DS after rapid dose escalation. nwgtwgsbln (kfjcpjrnoj )
Positive
07 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free